Organisation paid for research Program year 2025 Source: CMS Open Payments

Virginia Commonwealth Univ

Neither a doctor nor a teaching hospital

Research payments

$1,138,042

431 payments

Through program year 2025, Virginia Commonwealth Univ is reported as receiving $1,138,042 in research payments, across 431 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$243,781	31
2024	Research	$115,615	278
2023	Research	$222,723	33
2022	Research	$327,241	55
2021	Research	$115,315	11
2020	Research	$45,169	18
2019	Research	$68,199	5

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $448,322 125 payments
Merck Sharp & Dohme Corporation $326,102 3 payments
Jazz Pharmaceuticals Inc. $151,375 6 payments
Novo Nordisk AS $137,787 277 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $33,029 2 payments
Bayer HealthCare Pharmaceuticals Inc. $20,645 4 payments
Davol Inc. $7,000 2 payments
Celgene Corporation $6,350 1 payment
Siemens Medical Solutions USA, Inc. $5,911 8 payments
Mylan Inc. $967 1 payment

Studies the money was for Research payments · program years 2019–2025

Master Protocol to Assess the Safety and Antitumor Activity of Genetic $208,092 37 payments
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy $152,759 1 payment
A Phase 3 Randomized Trial for Patients With de Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin Go to Cpx351 With Go $135,375 1 payment
T cell Immune Checkpoint Inhibition Plus Hypomethylation for Breast Cancer a Neoadjuvant Window Trial $119,173 1 payment
Nn9536-7752 $78,328 257 payments
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $72,296 28 payments
T cell Immune Checkpoint Inhibition Plus Hypomethylation for Breast Cancer - a Neoadjuvant Window Trial $54,170 1 payment
A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $40,995 12 payments
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Eff $39,262 17 payments
A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy I $36,196 9 payments

What the money was spent on Research payments · program years 2019–2025

Other $1,522 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.